Dishman Carbogen Amcis Limited has informed the Exchange regarding 'DISCLOSURE PURSUANT TO REGULATIONS 30 AND 51 OF SEBI (LODR) REGULATIONS, 2015: COMPANY S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SITE, CHINA'.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Microcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis's wholly-owned subsidiary, Carbogen Amcis (Shanghai) Co. Ltd., has received a Drug Manufacturing License from China's National Medical Product Administration (NMPA) for its Shanghai facility. This regulatory clearance allows the subsidiary to legally manufacture pharmaceutical products at its China site. The company has disclosed this to the stock exchanges under SEBI LODR regulations 30 and 51. This marks an important regulatory milestone that enables commercial drug manufacturing operations in China.
Positive for shareholders — the manufacturing license legitimizes China operations and enables the subsidiary to tap into the large Chinese pharmaceutical market, potentially adding a new revenue stream. The stock may see a short-term positive reaction on regulatory de-risking, though actual revenue impact will depend on subsequent orders and capacity utilization.